TrialsgrambetaRCTs are beautiful

EMPA-REG OUTCOME

2015

Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes

In 7,020 patients with type 2 diabetes and cardiovascular disease, empagliflozin reduced cardiovascular death compared with placebo.

Result

Efficacy: CV death, MI or strokeHR 0.86

Below 1 favours empagliflozin, above 1 favours placebo.

Also reported: CV death down 38 %; HF hospitalisation down 35 %.

Original publication
Subtopic
SGLT2 inhibitors
Design
Double-blind RCT
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Zinman B, et al. N Engl J Med. 2015;373(22):2117-2128.doi 10.1056/NEJMoa1504720

Discussion & critique

First cardiovascular-outcomes trial to show an SGLT2-inhibitor benefit, unexpectedly driven by heart failure and CV death, launching the SGLT2i era.

Discussed in podcasts